1.	Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma Phase: Phase III Type: Supportive care, Treatment Status: Active Age: 3 to 21 at diagnosis Sponsor: NCI, Other Protocol IDs: ACNS0331, COG-ACNS0331, CDR0000365506, NCT00085735
2.	Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Under 3 Sponsor: NCI, Other Protocol IDs: ACNS0334, NCI-2009-00338, COG-ACNS0334, CDR0000483683, U10CA098543, NCT00336024
3.	Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 3 to 21 Sponsor: NCI, Other Protocol IDs: ACNS0332, NCI-2009-00336, COG-ACNS0332, CDR0000511991, U10CA098543, R01CA114567, NCT00392327
4.	Treatment of Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor Phase: Phase III Type: Treatment Status: Active Age: 3 to 21 at diagnosis Sponsor: Other Protocol IDs: SJMB03, SJCRH-SJMB03, NCT00085202
5.	Low-Dose Radiation Therapy and Combination Chemotherapy Following Surgery in Treating Children With Newly Diagnosed Primitive Neuroectodermal Tumor or Medulloblastoma Phase: Phase II Type: Supportive care, Treatment Status: Active Age: 3 to 30 at initial diagnosis Sponsor: Other Protocol IDs: CDR0000069075, CHP-693, CHP-IRB-2001-12-2301, NCI-V01-1680, NCT00031590
6.	Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Any age Sponsor: Other Protocol IDs: 05-122, MSKCC-05122, NCT00445965
7.	Antineoplaston Therapy in Treating Children With Brain Tumors Phase: Phase II Type: Treatment Status: Active Age: 6 months to 17 years Sponsor: Other Protocol IDs: CDR0000066490, BC-BT-10, NCT00003458
8.	Proton Radiotherapy for Pediatric Brain Tumors Requiring Partial Brain Irradiation Phase: Phase II Type: Natural history/Epidemiology, Treatment Status: Active Age: 1 to 25 Sponsor: NCI, Other Protocol IDs: 10-206, NCT01288235
9.	Concurrent Carboplatin and Reduced Dose Craniospinal Radiation for Medulloblastoma and Primitive Neuroectodermal Tumor (PNET) Phase: Phase II Type: Treatment Status: Active Age: 3 to 25 Sponsor: Other Protocol IDs: 06-1151, NCT01542736
10.	A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors Phase: Phase I Type: Treatment Status: Active Age: 3 to 22 Sponsor: Pharmaceutical / Industry Protocol IDs: 07-098, NCT00634231
11.	Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma Phase: No phase specified Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Under 3 at diagnosis Sponsor: Other Protocol IDs: SJYC07, SJCRH-SJYC07, NCT00602667
12.	Prospective Assessment of Quality of Life (QOL) in Pediatric Patients Treated With Radiation Therapy for Brain Tumors and Non-central Nervous System (Non-CNS) Malignancies Phase: No phase specified Type: Natural history/Epidemiology, Treatment Status: Active Age: 2 to 25 Sponsor: Other Protocol IDs: 2005P001629, NCT01115777
13.	Auto Transplant for High Risk or Relapsed Solid Tumor Phase: No phase specified Type: Treatment Status: Active Age: 70 and under Sponsor: Other Protocol IDs: 2011OC057, MT2011-09C, NCT01505569